These findings therefore recapitulate a unique and unrecognized advantage of STING agonism in itch treatment by the activation of TBK1-IRF3-dependent IFN-I response, suggesting that STING agonists can be used as a promising therapeutic approach for the management of pruritus with different etiologies. The gene discussed is TBK1; the disease is Pruritus.